Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer?

2015 Genitourinary Cancers Symposium

Published: 27 Feb 2015

Views: 2672

Rating:

Save

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Prof Nabid talks to ecancertv at ASCO GU 2015 about the results of a phase III study examining the "controversial" role of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2...

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Management of prostate cancer in Africa: Looking to the future

Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA

Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

Digital rectal examination is not useful as a solitary screening tool for...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

Single intensive screening intervention using PSA and Stockholm3 in combination...

Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality ( Prof Peter Albers - Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

More from ecancer